Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + etoposide + cisplatin
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral (cediranib), Intravenous (etoposide), Intravenous (cisplatin)
01
Overview
Cediranib + etoposide + cisplatin is a **combination drug regimen** investigated primarily as first-line therapy for **extensive-stage small-cell lung cancer (SCLC)** and metastatic neuroendocrine non-small-cell lung cancer (NEC)[1][4][7]. **Cediranib** is an oral, potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases, targeting angiogenesis—critical for tumor growth and metastasis. **Etoposide** is a topoisomerase II inhibitor, disrupting DNA synthesis, while **cisplatin** is a platinum-based DNA crosslinking agent, together exerting broad cytotoxic and anti-proliferative effects[1][4]. The regimen has shown promising clinical activity and manageable toxicity as first-line therapy for SCLC and NEC[1][4][7]. Cediranib is developed by AstraZeneca and has been studied under code name AZD2171/brand name Recentin[2][6][8].
- Other names
- cediranib maleate + etoposide + cisplatin
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on cediranib + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + etoposide + cisplatin.